What are the essential aspects of transcatheter LAA closure?

Ole De Backer and Philippe Garot discuss the rapid evolution of transcatheter left atrial appendage (LAA) occlusion.

They begin by contrasting patient selection in Europe and the US, where approaches diverge significantly: in Europe, very high bleeding risk remains the main criterion, while in the US, LAA closure is offered more broadly, even to patients without major bleeding concerns.

They then turn to the future, alluding to two pivotal trials comparing LAA occlusion to DOACs. From there, the conversation shifts to the technical side: what defines a state-of-the-art LAA occlusion today? Pre-procedural planning using cardiac CT or 3D-TEE is essential, and the role of post-procedural management, including antithrombotic therapy and imaging, is also highlighted.

Whether you are refining your own technique or following developments in the field, this exchange offers a concise and timely update on LAA closure in 2025.

This interview was filmed at EuroPCR 2025: see more videos here.